[go: up one dir, main page]

RU2019111862A3 - - Google Patents

Download PDF

Info

Publication number
RU2019111862A3
RU2019111862A3 RU2019111862A RU2019111862A RU2019111862A3 RU 2019111862 A3 RU2019111862 A3 RU 2019111862A3 RU 2019111862 A RU2019111862 A RU 2019111862A RU 2019111862 A RU2019111862 A RU 2019111862A RU 2019111862 A3 RU2019111862 A3 RU 2019111862A3
Authority
RU
Russia
Application number
RU2019111862A
Other versions
RU2758160C2 (ru
RU2019111862A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019111862A publication Critical patent/RU2019111862A/ru
Publication of RU2019111862A3 publication Critical patent/RU2019111862A3/ru
Application granted granted Critical
Publication of RU2758160C2 publication Critical patent/RU2758160C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019111862A 2016-09-20 2017-09-18 Новые антитела против фактора xi и их применения RU2758160C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016099474 2016-09-20
CNPCT/CN2016/099474 2016-09-20
PCT/EP2017/073410 WO2018054813A1 (en) 2016-09-20 2017-09-18 Novel antibodies against factor xi and uses thereof

Publications (3)

Publication Number Publication Date
RU2019111862A RU2019111862A (ru) 2020-10-22
RU2019111862A3 true RU2019111862A3 (ru) 2021-01-12
RU2758160C2 RU2758160C2 (ru) 2021-10-26

Family

ID=59914459

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019111862A RU2758160C2 (ru) 2016-09-20 2017-09-18 Новые антитела против фактора xi и их применения

Country Status (18)

Country Link
US (1) US10654941B2 (ru)
EP (2) EP3515947B1 (ru)
JP (1) JP2019537451A (ru)
KR (1) KR20190075920A (ru)
CN (1) CN110099927A (ru)
AR (1) AR109683A1 (ru)
AU (1) AU2017329645A1 (ru)
BR (1) BR112019005449A2 (ru)
CA (1) CA3037087A1 (ru)
DK (1) DK3515947T3 (ru)
ES (1) ES2984011T3 (ru)
FI (1) FI3515947T3 (ru)
IL (1) IL265383A (ru)
MX (1) MX2019003077A (ru)
PE (1) PE20191319A1 (ru)
RU (1) RU2758160C2 (ru)
TW (1) TW201825523A (ru)
WO (1) WO2018054813A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2017286432B2 (en) 2016-06-14 2020-09-24 Adimab, Llc Anti-coagulation factor XI antibodies
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第xi因子抗体および使用方法
CA3184718A1 (en) * 2020-07-02 2022-01-06 Lei Wang Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2022002233A1 (zh) * 2020-07-03 2022-01-06 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CN120923627A (zh) * 2024-05-08 2025-11-11 上海交通大学医学院附属瑞金医院 一种具有抗凝血活性的单克隆抗体及其应用
CN118359711B (zh) * 2024-06-20 2024-10-15 华淞(上海)生物医药科技有限公司 一种抗脊髓灰质炎病毒1型抗体及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
KR20050059332A (ko) * 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2014202009A1 (en) * 2007-11-21 2014-05-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
LT3002298T (lt) 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
TR201904662T4 (tr) * 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
CA2872926C (en) * 2012-05-10 2022-07-05 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) * 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CA3010224A1 (en) * 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies

Also Published As

Publication number Publication date
AR109683A1 (es) 2019-01-09
TW201825523A (zh) 2018-07-16
MX2019003077A (es) 2020-02-05
CN110099927A (zh) 2019-08-06
FI3515947T3 (fi) 2024-07-24
AU2017329645A8 (en) 2019-05-02
RU2758160C2 (ru) 2021-10-26
EP3515947A1 (en) 2019-07-31
WO2018054813A1 (en) 2018-03-29
ES2984011T3 (es) 2024-10-28
RU2019111862A (ru) 2020-10-22
EP4413996A2 (en) 2024-08-14
EP4413996A3 (en) 2024-10-23
PE20191319A1 (es) 2019-09-24
DK3515947T3 (da) 2024-07-29
CA3037087A1 (en) 2018-03-29
JP2019537451A (ja) 2019-12-26
AU2017329645A1 (en) 2019-04-04
US20190225705A1 (en) 2019-07-25
KR20190075920A (ko) 2019-07-01
EP3515947B1 (en) 2024-05-29
IL265383A (en) 2019-05-30
BR112019005449A2 (pt) 2019-10-01
US10654941B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
BR112018004986A2 (ru)
RU2019111862A3 (ru)
BR112017026640A2 (ru)
BR112019008315A2 (ru)
BR112019009373A2 (ru)
BR202016030146U2 (ru)
BR102016015741A2 (ru)
CN303537427S (ru)
CN303537770S (ru)
CN303394128S8 (ru)
CN303535881S (ru)
CN303536045S (ru)
CN303536130S (ru)
CN303536131S (ru)
CN303536211S (ru)
CN303536218S (ru)
CN303536221S (ru)
CN303536231S (ru)
CN303536357S (ru)
CN303536360S (ru)
CN303536519S (ru)
CN303537247S (ru)
CN303537332S (ru)
CN303537406S (ru)
CN303538946S (ru)